Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

AN INTERVENTIONAL PHASE 1B/2 STUDY TO EVALUATE THE SAFETY AND EFFICACY OF PF-08634404 MONOTHERAPY AND IN COMBINATION WITH OTHER ANTICANCER AGENTS IN ADULT PARTICIPANTS WITH LOCALLY ADVANCED OR METASTATIC RENAL CELL CARCINOMA

NCT07227415 is registered in ClinicalTrials.gov with Pfizer as lead sponsor.

NCT NCT07227415
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07227415 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
AN INTERVENTIONAL PHASE 1B/2 STUDY TO EVALUATE THE SAFETY AND EFFICACY OF PF-08634404 MONOTHERAPY AND IN COMBINATION WITH OTHER ANTICANCER AGENTS IN ADULT PARTICIPANTS WITH LOCALLY ADVANCED OR METASTATIC RENAL CELL CARCINOMA
Lead sponsor
Pfizer
Phase
Phase 1/2
Overall status
Recruiting
Start date
February 10, 2026
Completion date
November 1, 2028
Enrollment
224 (estimated)
Sites
183

Conditions

As the registry lists them; a condition with its own page is linked.

advanced or metastatic renal cell carcinoma, advanced renal cell carcinoma, carcinoma, renal cell, carcinoma, renal cell metastasis, carcinoma, renal cell, advanced, clear cell renal cell carcinoma, clear-cell metastatic renal cell carcinoma, metastatic renal cell cancer, metastatic renal cell carcinoma, metastatic renal cell carcinoma ( mrcc), metastatic/advanced renal cell carcinoma, renal cancer, renal neoplasm